A survey analysis found that professional burnout is increasing among physicians in the United States, according to data published in Mayo Clinic Proceedings. Tait D. Shanafelt , MD, at the division of hematology at the Mayo Clinic, and…
Ocular Therapeutix has received FDA acceptance of its new drug application filing for Dextenza to treat postoperative ocular pain, according to a company release.“This is an important milestone for the company and we will continue to work diligently with the FDA as they complete their review,” Amar Sawhney, PhD, president, CEO and chairman of Ocular Therapeutix, said in the release.
New data from ACCORD long-term follow-up study: cardiovascular mortality risk with tight glycemic control attenuates, retinopathy benefit remains, and brain function unaffected. Medscape Medical News
Glaucoma progressed after more than 8 years despite treatment in almost half of patients with low-pressure glaucoma, a study found.The retrospective study, conducted at the Wills Eye Hospital Glaucoma Research Center, included 49 eyes of 49 patients wh…
An engineer and an ophthalmologist are developing a portable sensor that can quickly and inexpensively determine whether an eye injury is mild or severe. The device, called OcuCheck, measures levels of vitamin C in the fluids that coat or leak from the…
VIENNA — At the Advanced Retinal Therapy meeting, Jennifer K. Sun, MD, speaks about the durability of effect of anti-VEGF therapy in diabetic eye disease. Although long-term results are needed, shorter term results from DRCR.net protocol studies suggest a sustained influence of anti-VEGF therapy on diabetic eye disease and visual acuity, and perhaps a reduced need for injections.